Abstract
The HER2 proto-oncogene, a member of the epidermal growth factor receptor family, is overexpressed in 20–30% of breast cancers. Genistein, the main soy isoflavone, interacts with estrogen receptors (ER) and it is also a potent tyrosine kinase inhibitor. Previously, our laboratory found that genistein delayed mammary tumor onset in transgenic mice that overexpress HER2 gene. Our goal was to define the mechanism through which genistein affects mammary tumorigenesis in HER2 overexpressing mice. We hypothesized that genistein inhibits HER2 activation and expression through ER-dependent and ER-independent mechanisms. Genistein inhibited total HER2 protein expression and tyrosine phosphorylation in BT-474, an ERα (−) and ERβ (+) human breast cancer cell line, however, E2 had no effect. Taken together, these data suggest that genistein has an ER-independent inhibitory effect, presumably, through tyrosine kinase inhibition activity. Genistein at 1.0 μM mimicked E2 and down-regulated HER2 protein phosphorylation when BT-474 was co-transfected with ERα, but not ERβ. Although E2 and overexpression of HER2 can promote mammary tumorigenesis, an inverse relationship between ER expression and HER2 overexpression has been found in human breast cancer. We cloned a 500-bp promoter region upstream of the HER2 transcription initiation site. Co-transfection with ERα, but not with ERβ, down-regulated HER2 promoter reporter in BT-474. At concentrations ≥1 μM, genistein inhibited HER2 promoter reporter in the absence of ERα. In conclusion, genistein at ≥1 μM inhibited HER2 protein expression, phosphorylation, and promoter activity through an ER-independent mechanism. In the presence of ERα, genistein mimicked E2 and inhibited HER2 protein phosphorylation. These data support genistein’s chemo-prevention and potential chemo-therapeutic roles in breast cancer.
Similar content being viewed by others
References
D.S. Subramaniam, C. Isaacs, Curr. Treat. Options Oncol. 6, 147–159 (2005)
D.G. Hicks, R.R. Tubbs, Hum. Pathol. 36, 250–261 (2005)
P. van der Geer, T. Hunter, R.A. Lindberg, Annu. Rev. Cell Biol. 10, 251–337 (1994)
N.E. Hynes, D.F. Stern, Biochim. Biophys. Acta 1198, 165–184 (1994)
Y. Bai, V. Giguere, Mol. Endocrinol. 17, 589–599 (2003)
I. Rubin, Y. Yarden, Ann. Oncol. 12(Suppl 1), S3–8 (2001)
S.L. Moulder, F.M. Yakes, S.K. Muthuswamy, R. Bianco, J.F. Simpson, C.L. Arteaga, Cancer Res. 61, 8887–8895 (2001)
J.D. Yager, N.E. Davidson, N. Engl. J. Med. 354, 270–282 (2006)
C. Dati, S. Antoniotti, D. Taverna, I. Perroteau, M. De Bortoli, Oncogene 5, 1001–1006 (1990)
D. Ingram, K. Sanders, M. Kolybaba, D. Lopez, Lancet 350, 990–994 (1997)
P.J. Ansell, S.C. Lo, L.G. Newton, C. Espinosa-Nicholas, D.D. Zhang, J.H. Liu, M. Hannink, D.B. Lubahn, Mol. Cell Endocrinol. 243, 27–34 (2005)
Z.M. Shao, M.L. Alpaugh, J.A. Fontana, S.H. Barsky, J. Cell Biochem. 69, 44–54 (1998)
N.S. Shenouda, C. Zhou, J.D. Browning, P.J. Ansell, M.S. Sakla, D.B. Lubahn, R.S. Macdonald, Nutr. Cancer 49, 200–208 (2004)
T.T. Wang, N. Sathyamoorthy, J.M. Phang, Carcinogenesis 17, 271–275 (1996)
T. Akiyama, J. Ishida, S. Nakagawa, H. Ogawara, S. Watanabe, N. Itoh, M. Shibuya, Y. Fukami, J. Biol. Chem. 262, 5592–5595 (1987)
A. Dalu, J.F. Haskell, L. Coward, C.A. Lamartiniere, Prostate 37, 36–43 (1998)
S.L. Parker, T. Tong, S. Bolden, P.A. Wingo, CA Cancer J. Clin. 46, 5–27 (1996)
D.M. Harris, E. Besselink, S.M. Henning, V.L. Go, D. Heber, Exp. Biol. Med. (Maywood) 230, 558–568 (2005)
R.S. MacDonald, J.-Y.Guo, M.S. Sakla, N. Shenouda, D.B. Lubahn, Phytoestrogen and Cancer (Iowa State Press, 2003)
Z. Jin, R.S. MacDonald, J. Nutr. 132, 3186–3190 (2002)
F. Pasleau, M. Grooteclaes, R. Gol-Winkler, Oncogene 8, 849–854 (1993)
M. Lacroix, G. Leclercq, Breast Cancer Res. Treat. 83, 249–289 (2004)
M. De Bortoli, C. Dati, J. Mammary Gland Biol. Neoplasia 2, 175–185 (1997)
E. Elstner, M. Linker-Israeli, J. Said, T. Umiel, S. de Vos, I.P. Shintaku, D. Heber, L. Binderup, M. Uskokovic, H.P. Koeffler, Cancer Res. 55, 2822–2830 (1995)
K.S. Russell, M.C. Hung, Cancer Res. 52, 6624–6629 (1992)
G.G. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nilsson, J.A. Gustafsson, Endocrinology 138, 863–870 (1997)
D.G. Bosc, R. Janknecht, J. Cell Biochem. 86, 174–183 (2002)
Y. Li, M. Bhuiyan, F.H. Sarkar, Int. J. Oncol. 15, 525–533 (1999)
C. Wang, M.S. Kurzer, Nutr. Cancer 28, 236–247 (1997)
G. Peterson, S. Barnes, Biochem. Biophys. Res. Commun. 179, 661–667 (1991)
G. Peterson, S. Barnes, Cell Growth Differ. 7, 1345–1351 (1996)
C.Y. Hsieh, R.C. Santell, S.Z. Haslam, W.G. Helferich, Cancer Res. 58, 3833–3838 (1998)
Z.M. Shao, Z.Z. Shen, J.A. Fontana, S.H. Barsky, Anticancer Res. 20, 2409–2416 (2000)
H.S. Seo, D.G. DeNardo, Y. Jacquot, I. Laios, D.S. Vidal, C.R. Zambrana, G. Leclercq, P.H. Brown, Breast Cancer Res. Treat. 99, 121–134 (2006)
M. Katdare, M. Osborne, N.T. Telang, Int. J. Oncol. 21, 809–815 (2002)
M.J. Messina, C.L. Loprinzi, J. Nutr. 131, 3095S–3108S (2001)
X. Huang, S. Chen, L. Xu, Y. Liu, D.K. Deb, L.C. Platanias, R.C. Bergan, Cancer Res. 65, 3470–3478 (2005)
C.H. Takimoto, K. Glover, X. Huang, S.A. Hayes, L. Gallot, M. Quinn, B.D. Jovanovic, A. Shapiro, L. Hernandez, A. Goetz, V. Llorens, R. Lieberman, J.A. Crowell, B.A. Poisson, R.C. Bergan, Cancer Epidemiol. Biomarkers Prev. 12, 1213–1221 (2003)
S. Matsuda, Y. Kadowaki, M. Ichino, T. Akiyama, K. Toyoshima, T. Yamamoto, Proc. Natl. Acad. Sci. USA 90, 10803–10807 (1993)
S. Antoniotti, D. Taverna, P. Maggiora, M.L. Sapei, N.E. Hynes, M. De Bortoli, Br. J. Cancer 70, 1095–1101 (1994)
J.M. Bosher, T. Williams, H.C. Hurst, Proc. Natl. Acad. Sci. USA 92, 744–747 (1995)
N.A. Kurpios, N.A. Sabolic, T.G. Shepherd, G.M. Fidalgo, J.A. Hassell, J. Mammary Gland Biol. Neoplasia 8, 177–190 (2003)
H.C. Hurst, Breast Cancer Res. 3, 395–398 (2001)
N. Platet, S. Cunat, D. Chalbos, H. Rochefort, M. Garcia, Mol. Endocrinol. 14, 999–1009 (2000)
S.P. Georgescu, J.H. Li, Q. Lu, R.H. Karas, M. Brown, M.E. Mendelsohn, Mol. Endocrinol. 19, 2491–2501 (2005)
V. Perissi, N. Menini, E. Cottone, D. Capello, M. Sacco, F. Montaldo, M. De Bortoli, Oncogene 19, 280–288 (2000)
R.J. Pietras, J. Arboleda, D.M. Reese, N. Wongvipat, M.D. Pegram, L. Ramos, C.M. Gorman, M.G. Parker, M.X. Sliwkowski, D.J. Slamon, Oncogene 10, 2435–2446 (1995)
A. Rannikko, A. Petas, S. Rannikko, H. Adlercreutz, Prostate 66, 82–87 (2006)
D.T. Zava, G. Duwe, Nutr. Cancer 27, 31–40 (1997)
V.L. Ernster, M.R. Wrensch, N.L. Petrakis, E.B. King, R. Miike, J. Murai, W.H. Goodson III, P.K. Siiteri, J. Natl. Cancer Inst. 79, 949–960 (1987)
P.J. Ansell, C. Espinosa-Nicholas, E.M. Curran, B.M. Judy, B.J. Philips, M. Hannink, D.B. Lubahn, Endocrinology 145, 311–317 (2004)
Acknowledgments
We would like to thank Mr. Jimmy Browning for his technical help, Dr. Wei Zhou for her assistance in HER2 promoter cloning, and Zhilin Liu for his statistical program advice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sakla, M.S., Shenouda, N.S., Ansell, P.J. et al. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocr 32, 69–78 (2007). https://doi.org/10.1007/s12020-007-9006-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-007-9006-1